Search

Your search keyword '"Spanish Group for Research on Sarcoma"' showing total 3 results
Start Over Author "Spanish Group for Research on Sarcoma" Topic sarcoma
3 results on '"Spanish Group for Research on Sarcoma"'

1. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)

Author

Garcia del Muro, Xavier, de Alava, Enrique, Artigas, Vicenç, Bague, Silvia, Braña, Alejandro, Cubedo, Ricardo, Cruz, Josefina, Mulet-Margalef, Nuria, Narvaez, Jose A, Martinez Tirado, Oscar, Valverde, Claudia, Verges, Ramona, Viñals, Joan, Martin-Broto, Javier, Spanish Group for Research on Sarcoma, [Garcia del Muro, Xavier] Inst Catala Oncol Hosp, Barcelona, Spain, [Mulet-Margalef, Nuria] Inst Catala Oncol Hosp, Barcelona, Spain, [de Alava, Enrique] Hosp Univ Virgen del Rocio, Seville, Spain, [Martin-Broto, Javier] Hosp Univ Virgen del Rocio, Seville, Spain, [Artigas, Vicenc] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Bague, Silvia] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Brana, Alejandro] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain, [Cubedo, Ricardo] Hosp Puerta Hierro Majadahonda, Madrid, Spain, [Cruz, Josefina] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain, [Narvaez, Jose A.] Hosp Univ Bellvitge, Barcelona, Spain, [Vinals, Joan] Hosp Univ Bellvitge, Barcelona, Spain, [Martinez Tirado, Oscar] Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain, [Valverde, Claudia] Hosp Univ Vall Hebron, Barcelona, Spain, and [Verges, Ramona] Hosp Univ Vall Hebron, Barcelona, Spain

Subjects
Cancer Research, medicine.medical_specialty, Soft Tissue Neoplasm, Core-needle-biopsy, medicine.medical_treatment, Antineoplastic Agents, Soft Tissue Neoplasms, Disease, Isolated limb perfusion, 030230 surgery, Toxicology, Targeted therapy, 03 medical and health sciences, Inflammatory myofibroblastic tumor, 0302 clinical medicine, Biopsy, Multidisciplinary management, medicine, Humans, Pharmacology (medical), Doxorubicin plus ifosfamide, Pharmacology, Randomized phase-ii, Soft tissue sarcoma, medicine.diagnostic_test, business.industry, General surgery, Soft tissue, Prognostic-factors, Sarcoma, Evidence-based medicine, medicine.disease, Clear-cell sarcoma, Surgery, Solitary fibrous tumor, Adjuvant chemotherapy, Treatment, Oncology, Chemotherapy, Adjuvant, Spain, 030220 oncology & carcinogenesis, Original Article, business, Clinical practice guidelines, High-dose doxorubicin
Abstract

The authors would like to thank Ron Clapp, and GEIS Clinical Research Center for their assistance in the preparation of the manuscript, Garcia Del Muro, X., De Alava, E., Artigas, V., Bague, S., Braña, A., Cubedo, R., Cruz, J., Mulet-Margalef, N., Narvaez, J.A., Martinez Tirado, O., Valverde, C., Verges, R., Viñals, J., Martin-Broto, J.

Published
2015

2. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).

Author

Garcia del Muro, Xavier, Alava, Enrique, Artigas, Vicenç, Bague, Silvia, Braña, Alejandro, Cubedo, Ricardo, Cruz, Josefina, Mulet-Margalef, Nuria, Narvaez, Jose, Martinez Tirado, Oscar, Valverde, Claudia, Verges, Ramona, Viñals, Joan, Martin-Broto, Javier, de Alava, Enrique, Artigas, Vicenç, Braña, Alejandro, Narvaez, Jose A, Viñals, Joan, and Spanish Group for Research on Sarcoma

Subjects
TISSUE wounds, CANCER treatment, SARCOMA, TUMOR diagnosis, BIOPSY, INTERDISCIPLINARY research, ANTINEOPLASTIC agents, COMBINED modality therapy, SOFT tissue tumors, DIAGNOSIS, TUMOR treatment
Abstract

Soft tissue sarcomas (STS) constitute an uncommon and heterogeneous group of tumours, which require a complex and specialized multidisciplinary management. The diagnostic approach should include imaging studies and core needle biopsy performed prior to undertaking surgery. Wide excision is the mainstay of treatment for localized sarcoma, and associated preoperative or postoperative radiotherapy should be administered in high-risk patients. Adjuvant chemotherapy was associated with a modest improvement in survival in a meta-analysis and constitutes a standard option in selected patients with high-risk STS. In metastatic patients, surgery must be evaluated in selected cases. In the rest of patients, chemotherapy and, in some subtypes, targeted therapy often used in a sequential strategy constitutes the treatment of election. Despite important advances in the understanding of the pathophysiology of the disease, the advances achieved in therapeutic results may be deemed still insufficient. Moreover, due to the rarity and complexity of the disease, the results in clinical practice are not always optimal. For this reason, the Spanish Group for Research on Sarcoma (GEIS) has developed a multidisciplinary clinical practice guidelines document, with the aim of facilitating the diagnosis and treatment of these patients in Spain. In the document, each practical recommendation is accompanied by level of evidence and grade of recommendation on the basis of the available data. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

3. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study

Author

Roberto Diaz-Beveridge, Luis Miguel De Sande-González, Antonio López Pousa, Jordi Rubió-Casadevall, Javier Martin-Broto, Pablo Luna, Juan Antonio Carrasco, Claudia M Valverde-Morales, Andres Poveda, Gloria Marquina, María Ángeles Vaz Salgado, Javier Martinez-Trufero, Antonio Gutierrez, Ana De Juan, Juana María Cano, Ibon Gurruchaga-Sotes, Isabel Sevilla, Josefina Cruz-Jurado, Jerónimo Martínez-García, Rosa Alvarez, David S. Moura, Institut Català de la Salut, [Martínez-Trufero J] Javier Martinez-Trufero, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. [De Sande-González LM] Medical Oncology Department, Complejo Asistencial Universitario de Leon, Leon, Spain. [Luna P] Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Martin-Broto J] Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBiS, CSIC, US, HUVR), Sevilla, Spain. [Álvarez R] Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain. [Marquina G] Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain. [Valverde-Morales CM] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, [Martínez-Trufero,J, Gurruchaga-Sotes,I] Javier Martinez-Trufero, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. [De Sande-González,LM] Medical Oncology Department, Complejo Asistencial Universitario de Leon, Leon, Spain. [Luna,P] Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Martin-Broto,J] Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBiS, CSIC, US, HUVR), Sevilla, Spain. [Álvarez,R] Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain. [Marquina,G] Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain. [Diaz-Beveridge,R] Medical Oncology Department, Hospital Politécnico La Fe, Valencia, Spain. [Poveda,A] Medical Oncology Department, Instituto Valenciano de Oncologia, Valencia, Spain. [Cano,JM] Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain. [Cruz-Jurado,J] Medical Oncology Department, Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain. [López Pousa,A] Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain. [Vaz Salgado,MA] Medical Oncology Department, Hospital Universitario Ramon y Cajal, RYCIS, CIBERONC, Madrid, Spain. [Valverde-Morales,C] Medical Oncology Department, Hospital Universitario Vall D’Hebron, Barcelona, Spain. [Sevilla,I] Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Medical Oncology Department, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Malaga, Spain. [Martínez-García,J] Medical Oncology Department, Hospital Virgen de la Arrixaca, Murcia, Spain. [Rubio-Casadevall,J] Medical Oncology Department, Instituto Catalan Oncologia, Girona, Spain. [De Juan,A] Medical Oncology Department, Hospital Marqués de Valdecilla, Santander, Spain. [Carrasco,JA] Medical Oncology Department, Hospital Alvaro Cunqueiro, Vigo, Spain. [Moura,DS] Instituto de Biomedicina de Sevilla (IBiS, CSIC, US, HUVR), Sevilla, Spain. [Gutiérrez,A] Hematology Department, Hospital Universitario Son Espases, 07010 Palma de Mallorca, Spain., and This research was funded by the Spanish Group for Research on Sarcoma (grant number: NA) and partially by PharmaMar. PharmaMar S.A. did not have any role in study design, or in collection, analysis and interpretation of data.

Subjects
0301 basic medicine, Oncology, Advanced soft tissue sarcomas, Cancer Research, Multivariate analysis, sarcoma, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings], Trabectedina, España, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma [Medical Subject Headings], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Metastasis, Prognostic score, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Trabectedin, Tumors de parts toves, Soft tissue sarcoma, Pronóstico, Soft tissue, Liposarcoma, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, prognostic score, GEISTRA, L-sarcoma, growth modulation index, prognostic score, sarcoma, trabectedin, 030220 oncology & carcinogenesis, trabectedin, Sarcoma, L-sarcoma, medicine.drug, medicine.medical_specialty, Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thiazoles::Thiamine::Thiamine Triphosphate [Medical Subject Headings], GEISTRA, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Analysis of Variance::Multivariate Analysis [Medical Subject Headings], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Neoplasms::Neoplasms by Site::Soft Tissue Neoplasms [DISEASES], epidemiología y bioestadística::epidemiología::usos de la epidemiología::efectividad [SALUD PÚBLICA], lcsh:RC254-282, Article, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma::Leiomyosarcoma [Medical Subject Headings], 03 medical and health sciences, Internal medicine, medicine, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma::Liposarcoma [Medical Subject Headings], neoplasias::neoplasias por localización::neoplasias de los tejidos blandos [ENFERMEDADES], Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], business.industry, Retrospective cohort study, medicine.disease, 030104 developmental biology, Spain, Medicaments - Eficàcia, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], Epidemiology and Biostatistics::Epidemiology::Uses of Epidemiology::Effectiveness [PUBLIC HEALTH], Leiomiosarcoma, business, growth modulation index
Abstract

The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI &gt, 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI &gt, 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky &lt, 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI &lt, 1, 41 (11.5%) with a GMI 1–1.33 and 118 (33.1%) with a GMI &gt, 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results